Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma
Open Access
- 12 January 2023
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 141 (2) , 180-193
Abstract
Cutaneous T-cell lymphoma (CTCL) is a devastating lymphoid malignancy characterized by the accumulation of malignant T cells in the dermis and epidermis. Skin lesions cause serious symptoms that hamper quality of life and are entry sites for bacterial infection, a major cause of morbidity and mortality in advanced diseases. The mechanism driving the pathological processes that compromise the skin barrier remains unknown. Here, we report increased transepidermal water loss and compromised expression of the skin barrier proteins filaggrin and filaggrin-2 in areas adjacent to TOX-positive T cells in CTCL skin lesions. Malignant T cells secrete mediators (including cytokines such as interleukin 13 [IL-13], IL-22, and oncostatin M) that activate STAT3 signaling and downregulate filaggrin and filaggrin-2 expression in human keratinocytes and reconstructed human epithelium. Consequently, the repression of filaggrins can be counteracted by a cocktail of antibodies targeting these cytokines/receptors, small interfering RNA–mediated knockdown of JAK1/STAT3, and JAK1 inhibitors. Notably, we show that treatment with a clinically approved JAK inhibitor, tofacitinib, increases filaggrin expression in lesional skin from patients with mycosis fungoides. Taken together, these findings indicate that malignant T cells secrete cytokines that induce skin barrier defects via a JAK1/STAT3-dependent mechanism. As clinical grade JAK inhibitors largely abrogate the negative effect of malignant T cells on skin barrier proteins, our findings suggest that such inhibitors provide novel treatment options for patients with CTCL with advanced disease and a compromised skin barrier.Keywords
This publication has 77 references indexed in Scilit:
- Bacterial Toxins Fuel Disease Progression in Cutaneous T-Cell LymphomaToxins, 2013
- Cytokines and the Skin BarrierInternational Journal of Molecular Sciences, 2013
- Infectious agents in cutaneous T-cell lymphomaJournal of the American Academy of Dermatology, 2011
- Skin immune sentinels in health and diseaseNature Reviews Immunology, 2009
- Filaggrin in the frontline: role in skin barrier function and diseaseJournal of Cell Science, 2009
- Loss-of-Function Mutations in the Filaggrin Gene Lead to Reduced Level of Natural Moisturizing Factor in the Stratum CorneumJournal of Investigative Dermatology, 2008
- Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndromeBritish Journal of Dermatology, 2008
- Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxinsBlood, 2006
- Cutaneous colonization with staphylococci influences the disease activity of Sézary syndrome: a potential role for bacterial superantigensBritish Journal of Dermatology, 1995
- Skin exudate levels of interleukin 6, interleukin i and other cytokines in mycosis fungoidesBritish Journal of Dermatology, 1990